GoodRx Announces Significant Savings on Antivirals, Medications and Vaccines for Cold & Flu Season
21 Settembre 2023 - 3:00PM
Business Wire
Company saved Americans more than $20
million on cold and flu treatments last season
GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings
and information, today announced it is offering new savings on
antivirals, medications and vaccines for the upcoming cold and flu
season. Last flu season (October 1, 2022 through April 30, 2023),
the CDC estimates that influenza was associated with more than 27
million illnesses, 300,000 hospitalizations, and 19,000 deaths,
showing the importance of Americans taking preventative measures to
protect themselves from the virus and understand the treatment
options available if they get sick. With these significant savings,
Americans can find affordable ways to prevent or treat seasonal
illnesses, regardless of insurance status.
For live updates on the progression and treatment rates of the
flu, COVID-19 and RSV, check out GoodRx’s “Tripledemic”
Tracker.
Big Savings on Flu Shots
The best way for consumers to protect themselves against the flu
is to get the annual flu shot between September and the end of
October, notes the CDC. However, the typical out-of-pocket cost for
a flu shot can be as high as $100, depending on the person’s
location and the type of vaccine.
To make flu shots more accessible to all Americans this season,
GoodRx is working directly with Walgreens, Walmart, and Weis to
offer one flat rate that includes the vaccine and all admin fees,
plus tax if applicable, with no surprise costs.
- 6 months to 64 years: Under $40 for the Fluarix or
Fluzone Quadrivalent
- 65 years and older: Under $70 for the Fluzone High-Dose
Quadrivalent
Cold & Flu
Treatments
For those who get the flu this season, GoodRx is making it easy
to access antivirals, which can shorten the duration and severity
of the flu, and other medications to help treat symptoms and
complications from the flu. Examples of savings on common
treatments include:
Drug Name
Lowest GoodRx Price
Avg % Savings w/
GoodRx
Albuterol (generic ProAir)
$14.71
53.1%
Amoxicillin
$5.43
53.0%
Azithromycin (Z-Pak)
$8.05
59.6%
Benzonatate
$9.64
57.1%
Oseltamivir (generic Tamiflu)
$20.82
68.5%
(Pricing information based on
September 2023 data and may vary at different pharmacies, and for
different forms, dosages and quantities)
COVID-19 & RSV
In addition to cold and flu, GoodRx is helping Americans prepare
for a rising number of COVID-19 and RSV cases. Trying to decide
which vaccines to get and when can be overwhelming, so Dr. Preeti
Parikh, Executive Medical Director of GoodRx, is providing the
following advice:
- Anyone six months and older should receive an annual flu shot
by the end of October. Those 65 and older should get the high-dose
version.
- Adults with high-risk conditions and those 60 years and older
should talk to their healthcare providers about the RSV vaccine, as
they may be more susceptible to complications from the virus.
- Parents of babies under the age of 8 months, or of babies ages
8 - 19 months old with high risk medical conditions, should talk to
their pediatrician about getting the newly approved RSV antibody
vaccine, starting October 1.
- The flu and COVID vaccines can ideally be taken together, but
Dr. Parikh recommends spacing out the RSV vaccine until more data
is available to confirm that taking them together won’t decrease
their efficacy.
Expert Advice from GoodRx
Health
To help consumers better navigate this year’s “tripledemic,”
GoodRx Health is offering a range of information and resources from
its team of medical experts, including doctors and pharmacists.
- COVID, Flu, and RSV: Your GoodRx Guide to Getting Vaccinated
this Fall
- COVID-19: Your GoodRx Guide
- Flu Vaccines: Your GoodRx Guide
- How to Find the COVID-19 Pills Paxlovid and Lagevrio
- RSV Vaccines: How Abrysvo vs. Arexvy Compare
- RSV: Your GoodRx Guide to Symptoms and Treatment
To learn more about how GoodRx can help with the upcoming cold
and flu season, visit: www.goodrx.com/cold-flu
About GoodRx
GoodRx is a leading resource for healthcare savings and
information that makes healthcare affordable and convenient for all
Americans. We offer consumers free access to transparent and lower
prices for brand and generic medications, affordable and convenient
medical provider consultations via telehealth, and comprehensive
healthcare research and information. Since 2011, we have helped
consumers save over $60 billion and are one of the most downloaded
medical apps over the past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings and the benefits of our
offerings to consumers. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to,
risks relating to our ability to achieve broad market education and
change consumer purchasing habits, changes in medication pricing
and pricing structures, our reliance on a limited number of
industry participants, the competitive nature of our industry,
risks related to government regulation of the internet, e-commerce,
consumer data and privacy, information technology and
cyber-security and the important factors discussed in the sections
entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for
the year ended December 31, 2022, as updated by our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2023, and our
other filings with the Securities and Exchange Commission. These
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921826959/en/
Media Contact Lauren Casparis press@goodrx.com
Grafico Azioni GoodRx (NASDAQ:GDRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni GoodRx (NASDAQ:GDRX)
Storico
Da Mag 2023 a Mag 2024